Definium Therapeutics (DFTX) Q4 FY25 earnings call

Definium Therapeutics is rapidly advancing its late-stage pipeline, with three pivotal Phase III readouts anticipated in 2026 for DT120 ODT in generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company maintains a strong financial position to support upcoming commercialization efforts, while also progressing its earlier-stage DT402 program for autism spectrum disorder. Management emphasizes scientific rigor and disciplined execution as it prepares for potential market entry.